DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,925,286 | +4.7% | 35,975 | +1.3% | 4.83% | +11.6% |
| Q2 2023 | $8,527,112 | +0.8% | 35,530 | +5.8% | 4.33% | -5.1% |
| Q1 2023 | $8,461,780 | -51.5% | 33,573 | -49.0% | 4.56% | -6.3% |
| Q4 2022 | $17,461,878 | +102.1% | 65,790 | +96.7% | 4.86% | +1.3% |
| Q3 2022 | $8,640,000 | +1.7% | 33,450 | -0.2% | 4.80% | +14.9% |
| Q2 2022 | $8,493,000 | -13.4% | 33,501 | +0.3% | 4.18% | +1.5% |
| Q1 2022 | $9,802,000 | -19.8% | 33,417 | -10.1% | 4.12% | -14.9% |
| Q4 2021 | $12,225,000 | +8.9% | 37,157 | +0.8% | 4.84% | -4.0% |
| Q3 2021 | $11,221,000 | +8.7% | 36,858 | -4.2% | 5.04% | +12.6% |
| Q2 2021 | $10,321,000 | +18.7% | 38,460 | -0.4% | 4.47% | +5.9% |
| Q1 2021 | $8,695,000 | +2.9% | 38,631 | +1.5% | 4.22% | +0.3% |
| Q4 2020 | $8,451,000 | +5.1% | 38,044 | +1.9% | 4.21% | -9.9% |
| Q3 2020 | $8,041,000 | +23.0% | 37,341 | +1.0% | 4.67% | +15.0% |
| Q2 2020 | $6,536,000 | +27.6% | 36,961 | -0.2% | 4.07% | +11.4% |
| Q1 2020 | $5,124,000 | -7.0% | 37,021 | +3.2% | 3.65% | +15.4% |
| Q4 2019 | $5,508,000 | +9.7% | 35,887 | +3.2% | 3.16% | -1.7% |
| Q3 2019 | $5,020,000 | +2.0% | 34,762 | +0.9% | 3.22% | +0.4% |
| Q2 2019 | $4,922,000 | +13.2% | 34,442 | +4.5% | 3.21% | +8.7% |
| Q1 2019 | $4,349,000 | +30.8% | 32,945 | +2.2% | 2.95% | +15.5% |
| Q4 2018 | $3,324,000 | -4.5% | 32,238 | +0.7% | 2.56% | +11.3% |
| Q3 2018 | $3,479,000 | +11.9% | 32,024 | +1.6% | 2.30% | +2.0% |
| Q2 2018 | $3,109,000 | +3.7% | 31,506 | +2.8% | 2.25% | +1.4% |
| Q1 2018 | $2,999,000 | +8.7% | 30,638 | +3.0% | 2.22% | +15.4% |
| Q4 2017 | $2,760,000 | +6.0% | 29,744 | -2.0% | 1.92% | +0.6% |
| Q3 2017 | $2,603,000 | +9.6% | 30,339 | +7.8% | 1.91% | +8.6% |
| Q2 2017 | $2,374,000 | -1.9% | 28,135 | -0.5% | 1.76% | -4.9% |
| Q1 2017 | $2,420,000 | +10.5% | 28,289 | +0.5% | 1.85% | +4.0% |
| Q4 2016 | $2,190,000 | +26.3% | 28,137 | +27.1% | 1.78% | +17.6% |
| Q3 2016 | $1,734,000 | +14.3% | 22,132 | +47.3% | 1.52% | +20.0% |
| Q2 2016 | $1,517,000 | +5.7% | 15,022 | -0.7% | 1.26% | +2.1% |
| Q1 2016 | $1,435,000 | -1.1% | 15,132 | -3.2% | 1.24% | -3.1% |
| Q4 2015 | $1,451,000 | +6.4% | 15,632 | -2.4% | 1.28% | +1.4% |
| Q3 2015 | $1,364,000 | +4.5% | 16,012 | +5.0% | 1.26% | +13.1% |
| Q2 2015 | $1,305,000 | +46.0% | 15,252 | +44.7% | 1.11% | +51.0% |
| Q1 2015 | $894,000 | – | 10,538 | – | 0.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |